Literature DB >> 29763342

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.

Mehmet Sitki Copur1, David Crockett1, Dron Gauchan1, Ryan Ramaekers1, Kris Mleczko1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29763342     DOI： 10.1200/JCO.2018.78.8240

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/β-catenin signaling.

Authors:  Hongyu Guan; Ting Zhu; Shanshan Wu; Shihua Liu; Bangdong Liu; Jueheng Wu; Junchao Cai; Xun Zhu; Xin Zhang; Musheng Zeng; Jun Li; Erwei Song; Mengfeng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

2.  Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients.

Authors:  Weihua Li; Yan Li; Lei Guo; Yutao Liu; Lin Yang; Jianming Ying
Journal:  JTO Clin Res Rep       Date:  2021-03-24

3.  HSD17B6 downregulation predicts poor prognosis and drives tumor progression via activating Akt signaling pathway in lung adenocarcinoma.

Authors:  Tian Tian; Fu Hong; Zhiwen Wang; Jiaru Hu; Ni Chen; Lei Lv; Qiyi Yi
Journal:  Cell Death Discov       Date:  2021-11-08

Review 4.  Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials.

Authors:  Syed Nasir Abbas Bukhari
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

5.  ZEB1-activated LINC01123 accelerates the malignancy in lung adenocarcinoma through NOTCH signaling pathway.

Authors:  Miao Zhang; Yaguang Han; Yi Zheng; Yan Zhang; Xin Zhao; Zhenlin Gao; Xinyan Liu
Journal:  Cell Death Dis       Date:  2020-11-15       Impact factor: 8.469
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.